Company type | Subsidiary |
---|---|
Nasdaq: CBST | |
Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
Founded | 1992 |
Defunct | 2015 |
Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez (president & CEO) |
Products | Product Pipeline |
Revenue | $926.4 million USD (2012) |
Parent | Merck & Co. |
Website | www.cubist.com |
Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA.
.[1] The company employed 638 people, mostly in Lexington, Massachusetts.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]